# Trastuzumab-Deruxtecan-Market-Report
Industry revenue for Trastuzumab Deruxtecan is estimated to rise to $156.6 billion by 2035 from $6.2 billion of 2024. The revenue growth of market players is expected to average at 34.2% annually for the period 2024 to 2035.
